Skyrizi vs Stelara Biosimilars — PatSnap Eureka
Skyrizi vs Stelara Biosimilars: AbbVie's Commercial Defense Strategy
As ustekinumab biosimilars reshape the IL-23 inhibitor market, AbbVie is executing a multi-indication expansion of risankizumab across IBD and PsA. This intelligence brief maps the mechanism, IP, and commercial dynamics defining the 2026 competitive landscape.
Why p19 Selectivity Is AbbVie's Core Differentiator Against Biosimilar Ustekinumab
Risankizumab (Skyrizi) targets the p19 subunit of IL-23 exclusively. This is a fundamentally different mechanism from ustekinumab (Stelara), which blocks the p40 subunit shared by both IL-12 and IL-23. By sparing IL-12 signalling, risankizumab preserves immune pathways that ustekinumab's broader blockade suppresses — a distinction that NIH-funded immunology research suggests may have meaningful clinical consequences in long-term immunosurveillance.
For AbbVie, this mechanistic selectivity is not merely a scientific footnote — it is the commercial narrative that allows Skyrizi to be positioned as a next-generation IL-23 inhibitor rather than a competitor within the same class as biosimilar ustekinumab. As multiple FDA-approved ustekinumab biosimilars commoditise the p40 inhibitor class with aggressive pricing, AbbVie's ability to draw a credible mechanistic distinction becomes the primary lever for formulary defence and prescriber preference.
The strategic implication is clear: in IBD and PsA — the two indications where Stelara biosimilars will create the most immediate payer pressure — risankizumab's p19 selectivity must be translated into real-world outcomes data that justifies premium pricing. PatSnap's life sciences intelligence platform tracks over 2 billion data points across patent filings, clinical trials, and regulatory submissions to map exactly how AbbVie is executing this translation.
Risankizumab vs Ustekinumab: Key Differentiators for Payers and Prescribers
Understanding the clinical, mechanistic, and commercial distinctions between Skyrizi and Stelara — and its biosimilars — is essential for formulary decision-making in 2026.
| Attribute | Skyrizi (Risankizumab) | Stelara / Biosimilars (Ustekinumab) |
|---|---|---|
| Primary Target | IL-23/p19 (selective) SELECTIVE | IL-12 + IL-23/p40 (dual blockade) |
| IL-12 Pathway Preserved | Yes — IL-12 signalling intact ADVANTAGE | No — IL-12 also suppressed |
| Approved Indications | PsO, PsA, Crohn's Disease, Ulcerative Colitis | PsO, PsA, Crohn's Disease, Ulcerative Colitis |
| Biosimilar Competition | None approved (patent protected) PROTECTED | Multiple US/EU biosimilars from 2023 |
| Route of Administration | Subcutaneous (maintenance); IV induction (IBD) | Subcutaneous (maintenance); IV induction (IBD) |
| Payer Pricing Pressure | Premium positioning — mechanistic differentiation | High — biosimilar entry driving price erosion PRESSURE |
Map the Complete Biosimilar Competitive Landscape
PatSnap Eureka surfaces patent filings, regulatory submissions, and clinical trial data for every ustekinumab biosimilar programme globally.
Skyrizi Indication Expansion and Biosimilar Market Dynamics
Patent and regulatory data from PatSnap Eureka illustrating the sequential indication build-out of risankizumab and the accelerating biosimilar entry into the ustekinumab market.
Risankizumab FDA Approval Milestones by Indication (2019–2024)
AbbVie's sequential indication expansion of Skyrizi — from plaque psoriasis through to ulcerative colitis — creates layered patent and commercial protection against biosimilar ustekinumab.
IL Pathway Blockade Profile: Risankizumab vs Ustekinumab
Risankizumab's selective p19 targeting blocks 100% of IL-23 while preserving all IL-12 signalling — the mechanistic distinction underpinning AbbVie's premium positioning vs biosimilar ustekinumab.
How AbbVie Is Building a Patent Thicket Around Skyrizi for 2026 and Beyond
AbbVie's defence of risankizumab mirrors the layered IP strategy it deployed for Humira — combining molecule patents, formulation claims, manufacturing process protection, and method-of-treatment filings across each new indication.
Core Composition-of-Matter Patents
The foundational risankizumab antibody patents cover the specific anti-IL-23/p19 monoclonal antibody composition, its CDR sequences, and binding characteristics. These form the innermost ring of AbbVie's IP defence and are the hardest for biosimilar developers to design around. PatSnap Analytics maps the full family tree of these core filings across 40+ jurisdictions.
Hardest to challengeSubcutaneous Formulation & Delivery Patents
Formulation patents covering the specific excipient composition, concentration, pH, and device used for subcutaneous delivery of risankizumab extend effective commercial exclusivity beyond the core molecule. These are filed as continuation patents and cover the precise formulation approved by regulators — meaning any biosimilar must either match exactly or seek separate regulatory approval for an alternative formulation.
Extends exclusivity windowCell Line & Process Patents
Manufacturing process patents covering the specific cell lines, fermentation conditions, and purification methods used to produce risankizumab create an additional barrier. Even if a biosimilar developer achieves structural similarity, process patent claims can require licensing or design-around — adding cost and timeline risk. The European Patent Office has upheld similar process claims for other biologics in precedent-setting decisions.
Raises biosimilar cost barrierMethod-of-Treatment Patents per New Indication
Each new indication approval — Crohn's disease, ulcerative colitis, psoriatic arthritis — generates a new tranche of method-of-treatment patent filings covering the specific dosing regimens, patient populations, and clinical endpoints. This means AbbVie's IP portfolio grows with every regulatory milestone, creating a thicket that becomes progressively denser as Skyrizi's label expands. PatSnap customers in biopharma use this exact analysis to time biosimilar entry strategies.
Grows with each approvalFour Commercial Dynamics Shaping the Skyrizi vs Biosimilar Ustekinumab Battle in 2026
These signals — derived from patent filing patterns, regulatory submissions, and clinical trial registrations — define the competitive terrain AbbVie is navigating.
Mechanistic Differentiation as Formulary Defence
AbbVie's medical affairs strategy centres on translating p19 selectivity into formulary positioning arguments with PBMs and payers. The preservation of IL-12 signalling is being framed as a clinically meaningful distinction — particularly for patients with concurrent infection risk or those in whom IL-12-mediated immune responses are important. This narrative is designed to justify step-therapy exceptions that keep Skyrizi accessible even when biosimilar ustekinumab is preferred on formulary.
IBD as the Critical Battleground Indication
Crohn's disease and ulcerative colitis represent the highest-value indications for both risankizumab and ustekinumab biosimilars. Gastroenterology is a specialty where physician relationships and clinical trial data carry enormous weight in prescribing decisions. AbbVie's investment in real-world evidence programmes for Skyrizi in IBD — including head-to-head observational data — is intended to create a body of evidence that biosimilar ustekinumab, without originator-level clinical investment, cannot match.
Ustekinumab Biosimilar Entry: Competitive Pressure by Indication
The number of biosimilar ustekinumab programmes targeting each major indication reflects where payer pressure on Skyrizi will be most intense heading into 2026.
Biosimilar Ustekinumab Programmes by Indication (Indicative Competitive Pressure)
Crohn's disease and plaque psoriasis attract the highest number of biosimilar ustekinumab programmes — directly overlapping with Skyrizi's core commercial indications.
AbbVie's Four-Layer Skyrizi Commercial Defence Architecture
AbbVie's defence of Skyrizi operates across four simultaneous layers — IP, clinical evidence, payer engagement, and indication expansion — mirroring the Humira defence playbook.
Skyrizi vs Stelara Biosimilars — key questions answered
Risankizumab (Skyrizi) is a selective IL-23/p19 inhibitor developed by AbbVie, meaning it targets only the p19 subunit of IL-23. Ustekinumab (Stelara) targets the p40 subunit shared by both IL-12 and IL-23. This selectivity gives risankizumab a more targeted mechanism of action in inflammatory diseases such as Crohn's disease, ulcerative colitis, and psoriatic arthritis, potentially offering a differentiated safety and efficacy profile compared to the broader IL-12/23 blockade of ustekinumab.
Stelara (ustekinumab) has been a dominant biologic in Crohn's disease, ulcerative colitis, and psoriatic arthritis — the same indications where AbbVie is expanding Skyrizi. As multiple ustekinumab biosimilars entered the US and EU markets from 2023 onward, payers and gastroenterologists gained access to lower-cost IL-12/23 inhibitors. This creates pricing pressure and formulary competition directly in the patient populations AbbVie is targeting for Skyrizi uptake, making commercial differentiation and IP protection critical strategic priorities for AbbVie heading into 2026.
AbbVie has been actively pursuing regulatory approvals and clinical trial data for risankizumab across inflammatory bowel disease (IBD) — specifically Crohn's disease and ulcerative colitis — as well as psoriatic arthritis (PsA). These expansions are central to AbbVie's strategy to position Skyrizi as a multi-indication IL-23 inhibitor that can capture patients switching from or being newly initiated versus ustekinumab and its biosimilars, leveraging the more selective p19 mechanism as a clinical and commercial differentiator.
AbbVie's commercial defense strategy for Skyrizi involves layered IP protection across the molecule itself, manufacturing processes, formulation patents, and method-of-treatment claims for specific indications. By filing continuation patents and pursuing new use patents as Skyrizi gains additional approvals in IBD and PsA, AbbVie extends the effective exclusivity window. This multi-layered approach mirrors AbbVie's well-documented strategy with Humira and is designed to create a patent thicket that raises the barrier for any future risankizumab biosimilar entrant.
Multiple ustekinumab biosimilars have entered or are entering the US and EU markets, including candidates from manufacturers such as Amgen, Sandoz, Teva, and others. These biosimilars target the same p40 subunit mechanism as Stelara and are approved for the same indications including Crohn's disease, ulcerative colitis, psoriatic arthritis, and plaque psoriasis. Their entry introduces significant price erosion to the ustekinumab market and shifts payer formulary dynamics in ways that directly affect the competitive landscape for Skyrizi.
The selective targeting of the p19 subunit of IL-23 — rather than the p40 subunit shared with IL-12 — is AbbVie's core scientific differentiator for Skyrizi. By sparing IL-12 signaling, risankizumab preserves certain immune pathways that ustekinumab's broader blockade affects. AbbVie uses this mechanistic distinction in its medical affairs and commercial messaging to position Skyrizi as a next-generation IL-23 inhibitor with a potentially improved benefit-risk profile, particularly relevant as biosimilar ustekinumab commoditises the p40 inhibitor class.
Need deeper intelligence on the Skyrizi vs ustekinumab biosimilar competitive landscape?
Ask PatSnap Eureka Your QuestionTrack Every Risankizumab Patent, Trial, and Biosimilar Filing in Real Time
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and competitive intelligence in biopharma.
References
- U.S. Food and Drug Administration (FDA) — Risankizumab (Skyrizi) approval history and biosimilar ustekinumab regulatory submissions.
- National Institutes of Health (NIH) — IL-23/p19 and IL-12/p40 cytokine pathway research in inflammatory bowel disease and psoriatic arthritis.
- European Patent Office (EPO) — Biologic manufacturing process patent precedents and continuation patent filing practices.
- PatSnap Analytics — Patent family tree analysis for risankizumab across global jurisdictions.
- PatSnap Life Sciences Intelligence — Biopharma patent landscape and clinical trial monitoring platform.
- PatSnap Customer Intelligence — Biopharma biosimilar entry timing analysis use cases.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Mechanism of action descriptions are derived from published scientific literature. Patent strategy analysis reflects publicly available patent filing data as indexed by PatSnap Eureka.
PatSnap Eureka searches patents and regulatory data to answer instantly.